J.M. Limacher

1.7k total citations · 1 hit paper
20 papers, 1.3k citations indexed

About

J.M. Limacher is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, J.M. Limacher has authored 20 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in J.M. Limacher's work include Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (6 papers) and Virus-based gene therapy research (4 papers). J.M. Limacher is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (6 papers) and Virus-based gene therapy research (4 papers). J.M. Limacher collaborates with scholars based in France, United States and Poland. J.M. Limacher's co-authors include Paul Basset, P. Hutin, M. C. Rio, C Wolf, Osvaldo L. Podhajcer, Jean‐Pierre Bellocq, Marie‐Pierre Chenard, Pierre Chambon, Isabelle Stoll and Corinne Wendling and has published in prestigious journals such as Nature, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

J.M. Limacher

19 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas

1990 973 citations Paul Basset, Jean‐Pierre Bellocq et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.M. Limacher France	8	722	662	520	295	165	20	1.3k
A Melchiori Italy	20	671 0.9×	603 0.9×	808 1.6×	552 1.9×	163 1.0×	35	1.7k
Shunsuke Yanoma Japan	21	323 0.4×	503 0.8×	417 0.8×	188 0.6×	215 1.3×	53	1.2k
C Wolf France	12	1.2k 1.7×	1.0k 1.6×	870 1.7×	518 1.8×	265 1.6×	12	2.1k
Liotta La United States	16	539 0.7×	679 1.0×	658 1.3×	562 1.9×	138 0.8×	23	1.7k
Ian Tomlinson United Kingdom	9	331 0.5×	471 0.7×	588 1.1×	222 0.8×	138 0.8×	12	1.4k
Paula Fukushima United States	13	389 0.5×	474 0.7×	319 0.6×	110 0.4×	367 2.2×	17	1.1k
Hiroshi Sato Japan	13	420 0.6×	497 0.8×	284 0.5×	128 0.4×	94 0.6×	15	828
Lucia Beviglia United States	13	267 0.4×	612 0.9×	708 1.4×	262 0.9×	108 0.7×	27	1.3k
Samuel Godár Austria	10	289 0.4×	491 0.7×	781 1.5×	317 1.1×	330 2.0×	11	1.5k
J. Bamat Switzerland	8	343 0.5×	306 0.5×	465 0.9×	189 0.6×	173 1.0×	9	980

Countries citing papers authored by J.M. Limacher

Since Specialization

Citations

This map shows the geographic impact of J.M. Limacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.M. Limacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.M. Limacher more than expected).

Fields of papers citing papers by J.M. Limacher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.M. Limacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.M. Limacher. The network helps show where J.M. Limacher may publish in the future.

Co-authorship network of co-authors of J.M. Limacher

This figure shows the co-authorship network connecting the top 25 collaborators of J.M. Limacher. A scholar is included among the top collaborators of J.M. Limacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.M. Limacher. J.M. Limacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Limacher, J.M., et al.. (2025). Case Report: Fatal Pneumocystis jirovecii Infection in an Elderly Man Receiving Adjuvant Paclitaxel and Trastuzumab Therapy for HER2‐Positive Breast Cancer. Case Reports in Oncological Medicine. 2025(1). 5515318–5515318.

Tourneau, Christophe Le, Philippe A. Cassier, Frédéric Rolland, et al.. (2020). 793 TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) human papilloma virus (HPV)-16+ cancers: clinical efficacy and immunogenicity. A841–A841. 3 indexed citations

Bastien, Bérangère, Luc Barraud, Murielle Gantzer, et al.. (2017). Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. Journal for ImmunoTherapy of Cancer. 5(1). 70–70. 47 indexed citations

Nemunaitis, John, Zsolt Pápai, H. Léna, et al.. (2015). TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P441–P441. 1 indexed citations

Quoix, Élisabeth, György Losonczy, Frédéric Forget, et al.. (2014). TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results. International Journal of Radiation Oncology*Biology*Physics. 90(5). S35–S35. 2 indexed citations

Quoix, Élisabeth & J.M. Limacher. (2014). Immunotherapy for non-small-cell lung cancer: current approaches. 3(1). 19–25. 2 indexed citations

Quoix, E., György Losonczy, Frédéric Forget, et al.. (2014). Time, a Phase 2B/3 Study Evaluating Tg4010 in Combination with First Line Therapy in Advanced Non Small Cell Lung Cancer (Nsclc). Phase 2B Results. Annals of Oncology. 25. iv364–iv364. 4 indexed citations

Wedemeyer, H., C Stanciu, V. Carreño, et al.. (2013). 62 PHASE II HCVac STUDY OF TG4040 IMMUNOTHERAPEUTIC IN COMBINATION WITH PEGIFNa2a AND RIBAVIRIN IN GENOTYPE 1 CHC TREATMENT NAÏVE PATIENTS: SVR24 FINAL RESULTS. Journal of Hepatology. 58. S28–S28. 1 indexed citations

Limacher, J.M., et al.. (2012). Therapeutic vaccination to treat chronic infectious diseases. Human Vaccines & Immunotherapeutics. 8(12). 1746–1757. 25 indexed citations

10.

Wedemeyer, Heiner, Ewa Janczewska, C Stanciu, et al.. (2012). 1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFNα2A AND RIBAVIRIN. Journal of Hepatology. 56. S552–S552. 5 indexed citations

11.

Muller, Danièle, Étienne Rouleau, Sandrine M. Caputo, et al.. (2011). An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition. BMC Medical Genetics. 12(1). 121–121. 15 indexed citations

12.

Acres, Bruce, Élisabeth Quoix, Rodryg Ramlau, et al.. (2009). Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. Journal of Clinical Oncology. 27(15_suppl). 3027–3027. 10 indexed citations

13.

Ramlau, Rodryg, V. Westeel, Zsolt Pápai, et al.. (2008). Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 8023–8023. 11 indexed citations

14.

Rixe, Olivier, Claude Linassier, J-P. Machiels, et al.. (2006). A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC). Journal of Clinical Oncology. 24(18_suppl). 2581–2581. 3 indexed citations

15.

Mennecier, B., Rodryg Ramlau, Janusz Rolski, et al.. (2005). P-963 A phase II study evaluating the clinical efficacy of TG4010(MVA-MUC1-IL2) in association with cisplatin and vinorelbine in patients with non small cell lung cancer. Lung Cancer. 49. S373–S373. 2 indexed citations

16.

Velu, Thierry, Rodryg Ramlau, E. Quoix, et al.. (2005). A phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with non small cell lung cancer. Journal of Clinical Oncology. 23(16_suppl). 7132–7132. 6 indexed citations

17.

Kurtz, Jean‐Emmanuel, G. Deplanque, Bernard Duclos, et al.. (1998). Paclitaxel–Anthracycline Combination Chemotherapy in Relapsing Advanced Ovarian Cancer after Platinum-Based Chemotherapy: A Pilot Study. Gynecologic Oncology. 70(3). 414–417. 7 indexed citations

18.

Lefèbvre, Olivier, C Wolf, J.M. Limacher, et al.. (1992). The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis.. The Journal of Cell Biology. 119(4). 997–1002. 146 indexed citations

19.

Basset, Paul, Jean‐Pierre Bellocq, C Wolf, et al.. (1990). A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 348(6303). 699–704. 973 indexed citations breakdown →

20.

Modry, Dennis, J.M. Limacher, & Anthony R.C. Dobell. (1981). Surgical treatment of the dilated aortic root in a child with Marfan's syndrome.. PubMed. 24(5). 500–2. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact